[{"orgOrder":0,"company":"Miist Therapeutics","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"MST-01","moa":"nAChR","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Miist Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Miist Therapeutics \/ Refactor Capital","highestDevelopmentStatusID":"6","companyTruncated":"Miist Therapeutics \/ Refactor Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Miist Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : The financing aims to advance the Miist clinical product MST-01, which is being evaluated for the treatment of smoking addiction.

                          Product Name : MST-01

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 05, 2025

                          Lead Product(s) : MST-01

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Refactor Capital

                          Deal Size : $7.0 million

                          Deal Type : Financing

                          blank